023910 — Dai Han Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapContrarian

Annual income statement for Dai Han Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	171,463	184,268	195,911	204,195	208,614
Cost of Revenue
Gross Profit	56,039	60,242	65,922	69,788	64,821
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	142,528	151,399	160,197	166,161	177,428
Operating Profit	28,935	32,868	35,714	38,034	31,186
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	30,433	33,451	36,734	42,329	33,153
Provision for Income Taxes
Net Income After Taxes	22,670	24,961	28,426	33,759	27,644
Net Income Before Extraordinary Items
Net Income	22,670	24,961	28,426	33,759	27,644
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	22,670	24,961	28,426	33,759	27,644
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3,790	4,184	4,842	5,740	4,697
Dividends per Share